v3.26.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Net revenues $ 17,258 $ 16,544 $ 15,846
Cost of sales 8,320 8,481 8,200
Gross profit 8,938 8,064 7,645
Research and development expenses, net 1,013 998 953
Selling and marketing expenses 2,686 2,541 2,336
General and administrative expenses 1,287 1,161 1,162
Intangible assets impairments 259 251 350
Goodwill impairment 0 1,280 700
Other asset impairments, restructuring and other items 1,050 1,388 718
Legal settlements and loss contingencies 467 761 1,043
Other loss (income) 18 (14) (49)
Operating income (loss) 2,157 (303) 433
Financial expenses – net 934 981 1,057
Income (loss) before income taxes 1,223 (1,284) (624)
Income taxes (benefit) (180) 676 (7)
Share in (profits) losses of associated companies – net (15) (1) (2)
Net income (loss) 1,418 (1,959) (615)
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests 7 (320) (56)
Net income (loss) attributable to Teva $ 1,410 $ (1,639) $ (559)
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ 1.23 $ (1.45) $ (0.5)
Diluted $ 1.21 $ (1.45) $ (0.5)
Weighted average number of shares (in millions):      
Basic 1,145 1,131 1,119
Diluted 1,163 1,131 1,119